Business
Orion announces agreement with Shilpa Medicare for Recombinant Human Albumin for European market
ORION CORPORATION PRESS RELEASE 23 MAY 2025 at 12.40 EEST Orion announces agreement with Shilpa Medicare for Recombinant Human Albumin for European market Orion Corporation and Shilpa Biocare Private Limited, a fully-owned subsidiary of Shilpa Medicare Limited (“Shilpa”), have entered into an agreement to commercialise Recombinant Human Albumin in Europe. Recombinant Human Albumin is a key plasma protein used in various therapeutic applications. Shilpa’s Recombinant Human Albumin is developed us
About this update from Orion Oyj Class A
[{"type":"image","alt":"Orion Oyj","displaySize":"","headline":null,"caption":"Orion Oyj","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":118,"url":"https://media.zenfs.com/en/globenewswire.com/81ce103a881cae9326d4e01207e6d4b0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PqzIu4PIU0vnnZUA5EUYng--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2NTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/81ce103a881cae9326d4e01207e6d4b0","width":300,"height":118}},"lazy":false},{"type":"text","content":"ORION CORPORATION PRESS RELEASE 23 MAY 2025 at 12.40 EEST","length":60,"tagName":"p"},{"type":"text","content":"Orion announces agreement with Shilpa Medicare for Recombinant Human Albumin for European market","length":96,"tagName":"p"},{"type":"text","content":"Orion Corporation and Shilpa Biocare Private Limited, a fully-owned subsidiary of Shilpa Medicare Limited (“Shilpa”), have entered into an agreement to commercialise Recombinant Human Albumin in Europe. Recombinant Human Albumin is a key plasma protein used in various therapeutic applications. Shilpa’s Recombinant Human Albumin is developed using a robust non-human expression system ensuring high safety, scalability, and virus-free production, addressing key limitations associated with human-derived albumin. The product is currently under development by Shilpa.","length":567,"tagName":"p"},{"type":"text","content":"Under the terms of the agreement, Orion will gain exclusive right to distribute, market and sell Shilpa’s Recombinant Human Albumin in Europe. Shilpa is entitled to receive from Orion certain development and regulatory milestone payments.","length":238,"tagName":"p"},{"type":"text","content":"“We are pleased to strengthen our strategic partnership with Shilpa by collaborating on this novel product,” said Satu Ahomäki, EVP Generics and Consumer Health, Orion Corporation. “Recombinant human albumin will strengthen our strategy and offering in value-add hospital generics, and we look forward to making it available across Europe.”","length":340,"tagName":"p"},{"type":"text","content":"“Partnering with Orion is a significant step in bringing our innovative recombinant product to patients across Europe and is a testimonial of our developmental and manufacturing capabilities to bring Recombinant Human Albumin to market,” said Madhav Bhutada, Managing Director, Shilpa...